Abingworth

Abingworth is a transatlantic life science investment firm dedicated to transforming breakthrough scientific discoveries into innovative medicines. The firm partners with entrepreneurs and management teams to provide capital and expertise to young biopharma companies across various stages of development. Abingworth employs a flexible investment strategy, encompassing seed and early-stage ventures, development-stage companies, and pioneering approaches such as Venture Investments in Public Equities (VIPEs) and Clinical Co-Development to accelerate drug development and commercialization.

The firm was founded in 1973 by London stockbrokers Peter Dicks and Hon. Anthony Montagu, initially as a broader investment firm. Abingworth established its dedicated biotech investment arm in 1987, marking its deep commitment to the life sciences sector. Over its extensive history, Abingworth has raised 15 funds focused on life sciences and healthcare, demonstrating a consistent track record in supporting the growth of innovative companies.

Abingworth has invested in over 190 life science companies, contributing to numerous product approvals, IPOs, and M&A transactions. Notable investments include companies like Alnylam Pharmaceuticals, Vaxcyte, Phathom Pharmaceuticals, Median Technologies, and Jasper Therapeutics. The firm's latest investment was in R1 Therapeutics in March 2026. Abingworth was acquired by The Carlyle Group in August 2022, enhancing its capital resources and operational capabilities.

The Abingworth team comprises professionals with significant prior experience in life sciences, offering hundreds of years of collective operational expertise. They provide comprehensive support to portfolio companies, assisting with leadership recruitment, drug target selection, business strategy, clinical development plans, and legal navigation. The firm also leverages a broad network of leading scientific and industry advisors to further support its portfolio.